Form 4: SeaStar Medical Director John Neuman Increases Stake Through RSU Vesting and New Award

SeaStar Medical Holding Corp. Director John Neuman increased his beneficial ownership to 92,000 shares through the vesting of 2,667 restricted stock units and the grant of an additional 4,000 restricted stock units.

Summary

• John Neuman, a Director of SeaStar Medical Holding Corp. (ICU), reported changes in his beneficial ownership.
• On June 4, 2025, 2,667 restricted stock units (RSUs) vested and converted into common stock. These RSUs were part of an 8,000 RSU grant from November 13, 2024, which vests in three annual installments.
• Following this vesting, Neuman's beneficial ownership was 88,000 shares, which includes 5,333 unvested restricted stock units (RSUs) from the November 2024 grant, now reported in Table I.
• On July 10, 2025, Neuman was granted an additional 4,000 RSUs.
• These newly granted 4,000 RSUs will vest in full on July 3, 2026.
• After the new RSU grant, Neuman's total beneficial ownership increased to 92,000 shares, which includes the remaining 5,333 unvested RSUs from the November 2024 grant and the newly granted 4,000 unvested RSUs from the July 2025 grant.

Sentiment

Score: 7

Explanation: The filing indicates an increase in director ownership through equity compensation, which is generally viewed positively as it aligns management interests with shareholders. There are no negative disclosures.

Positives

• Director John Neuman increased his beneficial ownership in SeaStar Medical Holding Corp. from 88,000 to 92,000 shares.
• The increase in ownership is due to the vesting of previously granted restricted stock units and the award of new restricted stock units, indicating continued compensation and alignment with shareholder interests.

Future Outlook

John Neuman's future beneficial ownership is expected to increase as the remaining 5,333 restricted stock units from the November 2024 grant vest in two approximately equal annual installments on June 4, 2026, and June 4, 2027, and the 4,000 restricted stock units granted on July 10, 2025, vest in full on July 3, 2026.

Industry Context

This Form 4 filing reflects routine insider compensation activity within the biotechnology or medical device industry, where equity grants like Restricted Stock Units are common mechanisms to align executive and director interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation through Restricted Stock Units (RSUs) with vesting schedules is a standard practice across various industries, including medical technology, for retaining and incentivizing directors and executives.
• The grant of 4,000 RSUs and the vesting of 2,667 RSUs for a director like John Neuman at SeaStar Medical Holding Corp. are typical forms of non-cash compensation.
• While specific compensation levels vary by company size, performance, and industry benchmarks (e.g., compared to directors at similar-stage biotech firms like Renalytix AI plc or Outset Medical, Inc.), the mechanism itself aligns with common corporate governance practices.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased equity ownership.

Next Steps

• Remaining 5,333 RSUs from the November 13, 2024 grant are expected to vest in two approximately equal annual installments on June 4, 2026, and June 4, 2027.
• The 4,000 RSUs granted on July 10, 2025, are expected to vest in full on July 3, 2026.

Key Dates

Recommendation

Keywords

SeaStar Medical Holding Corp, ICU, John Neuman, SEC Form 4, insider trading, beneficial ownership, restricted stock units, RSU, stock grant, director, equity compensation